Mazdutide Dosage Guide: GLP-1 + Glucagon Dual Agonist Explained
Mazdutide
Mazdutide is a dual GLP-1 receptor and glucagon receptor agonist developed for chronic weight management and metabolic disease. It combines GLP-1-related appetite and glucose signaling with glucagon-receptor activity involved in energy expenditure and lipid metabolism. Mazdutide is approved in China for chronic weight management and type 2 diabetes but is not currently FDA-approved in the United States.
How It Works
GLP-1 Receptor Activation → Satiety ↑ + Food Intake ↓ + Glucose Regulation ↑
Glucagon Receptor Activation → Energy Expenditure + Lipid Metabolism
Glucagon Receptor Activation → Energy Expenditure + Lipid Metabolism
Mazdutide activates both GLP-1 and glucagon receptors. GLP-1 receptor activity contributes to satiety, reduced food intake, glucose-dependent insulin signaling, and delayed gastric emptying. Its glucagon-receptor activity adds a second metabolic pathway associated with energy expenditure, lipid metabolism, and broader cardiometabolic effects.
Mazdutide is a dual GLP-1 / glucagon receptor agonist.
It does not activate the GIP receptor like tirzepatide or retatrutide.
Human clinical trials have evaluated once-weekly subcutaneous administration.
Gradual dose escalation has been used in clinical studies to improve gastrointestinal tolerability.
Mazdutide Research-Use Protocol
Important Evidence Distinction:
The 1 mg → 2 mg → 3–4 mg → up to 6 mg progression below preserves the research-use framework used on this page. Human mazdutide trials and approved treatment in China use study- or indication-specific dosing schedules, which are shown separately below.
The 1 mg → 2 mg → 3–4 mg → up to 6 mg progression below preserves the research-use framework used on this page. Human mazdutide trials and approved treatment in China use study- or indication-specific dosing schedules, which are shown separately below.
Low Weekly Start → Gradual Titration → Appetite + Metabolic Support
Standard Weekly Research-Use Titration
Weeks 1–4
1 mg weekly
Weeks 5–8
2 mg weekly
Weeks 9–12
3–4 mg weekly
Higher Research-Use Range
Up to ~6 mg weekly
Standard Reconstitution Example
Vial
10 mg
Diluent
2.0 mL bacteriostatic water
Concentration
5 mg/mL
Conversion
1 unit = 50 mcg
Dose Conversion Reference
1 mg = 20 units (0.20 mL)
2 mg = 40 units (0.40 mL)
3 mg = 60 units (0.60 mL)
4 mg = 80 units (0.80 mL)
6 mg = 120 units (1.20 mL)
Volume Note:
With a 10 mg vial mixed with 2.0 mL bacteriostatic water, higher doses such as 6 mg require more than a standard 1 mL syringe capacity. This is a limitation of the chosen concentration, not the dose itself.
With a 10 mg vial mixed with 2.0 mL bacteriostatic water, higher doses such as 6 mg require more than a standard 1 mL syringe capacity. This is a limitation of the chosen concentration, not the dose itself.
Weeks 1–4
Starting Dose
Dose
1 mg weekly
Frequency
Once weekly
Route
Subcutaneous
Weeks 5–8
Build Phase
Dose
2 mg weekly
Frequency
Once weekly
Route
Subcutaneous
Weeks 9–12
Standard Research-Use Range
Dose
3–4 mg weekly
Frequency
Once weekly
Route
Subcutaneous
Higher Research-Use Range
Advanced Range
Dose
Up to ~6 mg weekly
Frequency
Once weekly
Context
Higher research-use range
Simple Approach:
Mazdutide is commonly structured with gradual weekly titration. The research-use progression above should not be confused with a standardized approved dosing schedule. Human clinical studies have generally used defined escalation steps and target doses over longer treatment periods.
Mazdutide is commonly structured with gradual weekly titration. The research-use progression above should not be confused with a standardized approved dosing schedule. Human clinical studies have generally used defined escalation steps and target doses over longer treatment periods.
What the Clinical Research Actually Used
Earlier Dose-Escalation Research
Phase 2 studies evaluated several mazdutide dose-escalation schedules rather than one universal titration protocol.
Published schedules included 1.5 mg → 3 mg and 1.5 mg → 3 mg → 4.5 mg once weekly.
Other clinical programs used 2 mg → 4 mg → 6 mg once weekly, generally with approximately 4 weeks at each escalation step.
GLORY-1 Phase 3
Target Doses
4 mg or 6 mg weekly
Starting Dose
2 mg weekly
6 mg Escalation
2 mg → 4 mg → 6 mg
Treatment Period
48 weeks
Route
Subcutaneous, once weekly
GLORY-1 Weight-Loss Findings
At week 48, mean body-weight reduction was approximately 11.0% with 4 mg weekly.
At week 48, mean body-weight reduction was approximately 14.0% with 6 mg weekly.
Nearly half of participants in the 6 mg group achieved at least 15% weight reduction at week 48.
Improvements were also reported across prespecified cardiometabolic measures.
Why this matters:
The clinical evidence supports 4 mg and 6 mg as important mazdutide doses, but it does not establish the separate 1 → 2 → 3–4 → 6 mg research-use progression on this page as the official clinical titration.
The clinical evidence supports 4 mg and 6 mg as important mazdutide doses, but it does not establish the separate 1 → 2 → 3–4 → 6 mg research-use progression on this page as the official clinical titration.
Higher-Dose 9 mg Research
9 mg Clinical Research
Dose Studied
9 mg once weekly
Route
Subcutaneous
Research Context
Adults with higher-BMI obesity
Research Findings
Phase 2 research with 9 mg reported substantial weight reduction in adults with BMI ≥30 kg/m².
A subsequent Phase 3 GLORY-2 trial studied 9 mg once weekly for 60 weeks in adults with obesity, including participants with and without type 2 diabetes.
The existence of 9 mg clinical research does not mean that 9 mg should automatically be added to the standard research-use titration shown elsewhere on this page.
Higher-Dose Distinction:
The 9 mg dose has direct human clinical-research precedent, but it belongs in a higher-dose clinical-research category rather than being treated as the routine next step after the 6 mg framework.
The 9 mg dose has direct human clinical-research precedent, but it belongs in a higher-dose clinical-research category rather than being treated as the routine next step after the 6 mg framework.
Approval Status
China
Weight Management
Approved June 2025
Type 2 Diabetes
Approved September 2025
United States
FDA Approval
Not currently approved
U.S. Status
Not an FDA-approved prescription medication
Important Status Update:
Mazdutide should no longer be described simply as an “investigational compound” without qualification. It is an approved medication in China for specific indications while remaining unapproved in the United States.
Mazdutide should no longer be described simply as an “investigational compound” without qualification. It is an approved medication in China for specific indications while remaining unapproved in the United States.
How to Use Mazdutide (Timing & Injection)
Frequency
Once weekly
Clinical Route
Subcutaneous
Use Style
Long-term, titration-based treatment in clinical studies
Specific Time of Day
No demonstrated clinical advantage
Timing Notes
Human clinical trials use once-weekly administration.
Using a consistent weekly schedule can make treatment tracking easier.
A specific morning-versus-evening advantage has not been established.
Gradual dose escalation is more important than exact clock timing.
Common Research Contexts
Weight-management research
Type 2 diabetes and glycemic-control research
Cardiometabolic-risk research
Liver-fat and broader metabolic research
Research-Use vs Clinical Dosing
Research-Use Framework
Commonly Discussed Range
1–6 mg weekly
Framework
1 → 2 → 3–4 → up to 6 mg
Clinical Evidence
GLORY-1
4 mg and 6 mg target doses
Higher-Dose Research
9 mg studied separately
Frequency
Once weekly
Simple Takeaway:
The commonly circulated research-use range overlaps with doses evaluated clinically, but overlap does not make the research-use titration itself a validated clinical schedule.
The commonly circulated research-use range overlaps with doses evaluated clinically, but overlap does not make the research-use titration itself a validated clinical schedule.
Reconstitution & Dosing
Research-Vial Context:
The vial-and-bacteriostatic-water calculations below represent a research-use concentration framework. They should not be interpreted as the formulation or preparation method used in approved Chinese mazdutide products or clinical trials.
The vial-and-bacteriostatic-water calculations below represent a research-use concentration framework. They should not be interpreted as the formulation or preparation method used in approved Chinese mazdutide products or clinical trials.
Common Research-Vial Context
Typical Vial
5 mg / 10 mg
Research-Use Dilution
2–3 mL bacteriostatic water commonly discussed
Example: 10 mg Vial + 2.0 mL BAC Water
Vial
10 mg
Water
2.0 mL
Concentration
5 mg/mL
Conversion
1 unit = 50 mcg
Dose Reference
20 units = 1 mg
40 units = 2 mg
60 units = 3 mg
80 units = 4 mg
120 units = 6 mg
Volume Note:
At 5 mg/mL, 6 mg equals 1.20 mL or 120 units. That exceeds the capacity of a standard 1 mL U-100 insulin syringe. This is a limitation of the example research concentration rather than the dose itself.
At 5 mg/mL, 6 mg equals 1.20 mL or 120 units. That exceeds the capacity of a standard 1 mL U-100 insulin syringe. This is a limitation of the example research concentration rather than the dose itself.
Research-Vial Handling
Add the selected sterile diluent slowly to the vial.
Gently swirl rather than shaking vigorously.
Allow the material to dissolve completely.
Label the vial with the concentration and preparation date.
Follow formulation-specific storage information whenever available.
Storage & Shelf Life
Approved / Clinical Products
Approved mazdutide products should be stored according to the manufacturer and local prescribing information for the specific formulation.
Manufactured clinical products should not be treated like generic lyophilized research vials.
Research-Vial Context
Lyophilized research material is commonly stored cold, dry, sealed, and protected from light according to supplier guidance.
Reconstituted research preparations are commonly refrigerated.
A universal 30-day post-reconstitution shelf life should not be assumed for every independently prepared mazdutide formulation.
Stability depends on formulation, concentration, diluent, sterility, container, and manufacturer specifications.
Cycle Length & Long-Term Use
Dose Escalation → Target Dose → Ongoing Treatment → Reassess as Needed
Clinical Context
Use Style
Long-term, titration-based treatment
GLORY-1 Treatment
48 weeks
GLORY-2 Treatment
60 weeks
Routine Cycling
Not an established clinical requirement
When to Reassess
Gastrointestinal tolerance becomes difficult.
Appetite suppression interferes with adequate nutrition.
Weight or metabolic response changes substantially.
Dose escalation is being considered despite significant adverse effects.
The treatment goal or clinical indication changes.
Why this is different:
Mazdutide clinical studies use prolonged continuous treatment rather than routine short peptide cycles. A fixed 8–12 week review point can still be useful as a research-use reassessment interval, but it should not be presented as a required clinical cycle or mandatory break.
Mazdutide clinical studies use prolonged continuous treatment rather than routine short peptide cycles. A fixed 8–12 week review point can still be useful as a research-use reassessment interval, but it should not be presented as a required clinical cycle or mandatory break.
Monitoring During Use
Body weight and waist circumference
Appetite, satiety, and nutritional intake
Nausea, vomiting, diarrhea, constipation, or other gastrointestinal symptoms
Hydration status
Blood glucose and A1C when clinically relevant
Blood pressure and other cardiometabolic markers when clinically appropriate
Energy, fatigue, and overall tolerability during dose escalation
Benefits & Clinical Findings
Randomized human trials demonstrate clinically meaningful reductions in body weight.
Mazdutide has demonstrated improvements across multiple cardiometabolic measures.
Clinical research supports effects on glycemic control in adults with type 2 diabetes.
The glucagon-receptor component provides a metabolic mechanism distinct from GLP-1-only therapies.
Higher-dose 9 mg clinical research has demonstrated additional weight-loss activity in adults with higher-BMI obesity.
Evidence Context:
Mazdutide has moved beyond early experimental evidence and now has Phase 3 human data and regulatory approval in China. Outcomes should still be interpreted according to dose, population, indication, and treatment duration.
Mazdutide has moved beyond early experimental evidence and now has Phase 3 human data and regulatory approval in China. Outcomes should still be interpreted according to dose, population, indication, and treatment duration.
Potential Side Effects & Safety Considerations
Gastrointestinal adverse events are the most commonly reported side effects.
Nausea, diarrhea, and vomiting occur more frequently with mazdutide than placebo in clinical studies.
Most gastrointestinal events in GLORY-1 were reported as mild to moderate.
Higher-dose research has also reported substantial rates of nausea, diarrhea, and vomiting during treatment.
Longer-term cardiovascular safety and broader experience across diverse populations continue to be studied.
Important Notes
Mazdutide is a dual GLP-1 receptor and glucagon receptor agonist.
It should not be described as a GIP-containing dual agonist; its second receptor target is the glucagon receptor.
Mazdutide received approval in China for chronic weight management in June 2025.
It received an additional approval in China for glycemic control in adults with type 2 diabetes in September 2025.
Mazdutide is not currently FDA-approved in the United States.
The 1 mg → 2 mg → 3–4 mg → up to 6 mg progression shown on this page is preserved as a research-use framework rather than presented as the official clinical titration.
Phase 3 GLORY-1 studied 4 mg and 6 mg target doses and used a 2 mg starting dose with staged escalation.
Separate human studies have now evaluated 9 mg once weekly in higher-BMI obesity populations.
The existence of 9 mg clinical research does not make 9 mg a routine extension of the 1–6 mg research-use framework.
Mazdutide clinical studies use long-term weekly treatment rather than routine short on/off peptide cycles.
Research-vial BAC-water ratios, syringe-unit conversions, and storage estimates shown on this page should be distinguished from approved or clinical-trial formulations.
Research vs. Clinical Context:
Mazdutide now has Phase 3 human evidence and regulatory approval in China. This page preserves separately circulated research-use dosing and reconstitution frameworks while clearly distinguishing them from the doses, formulations, and treatment schedules studied clinically or used in approved pharmaceutical products.
Mazdutide now has Phase 3 human evidence and regulatory approval in China. This page preserves separately circulated research-use dosing and reconstitution frameworks while clearly distinguishing them from the doses, formulations, and treatment schedules studied clinically or used in approved pharmaceutical products.
Important Disclaimer
Mazdutide is approved in China for specific medical indications but is not currently FDA-approved in the United States. The research-use dosing, reconstitution, and vial-conversion information shown on this page is educational and should not be confused with approved prescribing instructions or manufactured pharmaceutical formulations.
Research & References
Primary Research
- Zhu D, Zhao J, Cai H, et al. Mazdutide versus Placebo in Chinese Adults with Type 2 Diabetes. Nature. 2026.
- Guo L, Zhang B, Xue X, et al. Mazdutide versus Dulaglutide in Chinese Adults with Type 2 Diabetes. Nature. 2026.
- Luo Y, Jiang H, Shi B, et al. Mazdutide versus Semaglutide for the Treatment of Type 2 Diabetes and Obesity: Rationale, Design and Baseline Data of DREAMS-3 Phase 3 Trial. Contemporary Clinical Trials. 2026.
Reviews & Supporting Research
- Kamrul-Hasan ABM, et al. Efficacy and Safety of the Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta-Analysis. Diabetes, Obesity and Metabolism. 2026.
- Nalisa DL, Cuboia N, Dyab E, et al. Efficacy and Safety of Mazdutide on Weight Loss Among Diabetic and Non-Diabetic Patients: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Frontiers in Endocrinology. 2024.
Research Note: Mazdutide is a synthetic dual glucagon receptor (GCGR) and GLP-1 receptor agonist studied primarily in Chinese Phase 3 trials for type 2 diabetes and obesity. Dosing protocols reflect the titration schedules used in these clinical trials; most published clinical experience to date has been in Chinese populations.
Comments
Post a Comment